Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: TMT
YouGov has delivered strong results that demonstrate the success of its shift in its business model towards a real-time data analytics business with a growing subscription revenue base. It continues to innovate, developing new products and services and augmenting the existing offering and is further expanding its geographic reach, with the investment supported by the cash-rich balance sheet. A new five-year plan is expected to be set out in Spring 2019 and we anticipate that this will also have ambitious targets for growth and earnings that will support the premium rating.
YouGov |
Trading at top end of five-year plan |
Final Results |
Media |
9 October 2018 |
Share price performance
Business description
Next events
Analysts
YouGov is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||
YouGov has delivered strong results that demonstrate the success of its shift in its business model towards a real-time data analytics business with a growing subscription revenue base. It continues to innovate, developing new products and services and augmenting the existing offering and is further expanding its geographic reach, with the investment supported by the cash-rich balance sheet. A new five-year plan is expected to be set out in Spring 2019 and we anticipate that this will also have ambitious targets for growth and earnings that will support the premium rating.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
EV/EBITDA (x) |
P/E |
Yield |
07/16 |
88.2 |
14.4 |
8.5 |
1.4 |
36.9 |
55.4 |
0.3 |
07/17 |
107.0 |
17.9 |
10.5 |
2.0 |
27.3 |
44.9 |
0.4 |
07/18 |
116.6 |
26.9 |
15.6 |
3.0 |
19.0 |
30.3 |
0.6 |
07/19e |
132.0 |
27.5 |
17.2 |
3.5 |
18.5 |
27.5 |
0.8 |
07/20e |
141.0 |
29.5 |
18.3 |
4.0 |
17.1 |
25.8 |
0.9 |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Revenues and margins ahead
FY18 revenues were up 9% on prior year, 12% on a constant currency (CC) basis, despite the shift in the Custom Research business away from one-off projects holding that segment’s revenue performance flat. Data Products and Services continue to build at an impressive rate, up 30% and 26% respectively (CC). A shift in the allocation of cost from Custom Research to the centre (a more accurate reflection) flattered the improvement in operating margin, but stripping this back, the segmental margin still grew from 18.9% to 24.1%. At group level, the operating margin rose to 16.9% (FY17: 13.6%). The increasing sophistication of the tools and analysis, all based on the group’s proprietary data derived from its own panel, is enabling it to become more deeply embedded in its clients’ work flows and underpins the growing subscription base, as well as supporting margins.
Cash to invest and grow
The US remains the most important territory (47% FY18 revenue), with the group now operating in 50 national markets. Management is focused on building YouGov as a global partner in research data and analytics, requiring investment both on innovation and on building geographic reach. The group’s cash resource (£30.6m at the end of July) comfortably covers both objectives. Small bolt-on acquisitions are now also part of the armoury (Australian firm Galaxy was bought in December 2017 for A$1.25m; sports specialist SMG in May 2018 for £1m, with a structured earn-out). Our updated model indicates end FY19e cash of £30.1m.
Valuation: Premium sustained
YouGov is growing its top line well ahead of the market research sector (+3.3% in 2017: ESOMAR), while also improving the quality of its earnings as it builds its recurring revenue base. The current share price puts it on a rating well ahead of sectoral peers (see page 3), but considerably below the listed SaaS subscription businesses with which it has increasing commonality.
Delivery of strong FY18, good prospects FY19e
The salient points of the FY18 results are as follows:
■
A 9% increase in group revenues (12% at CC)
■
2% of revenue growth attributable to acquisitions
■
Adjusted operating profits up 35% (figures quoted here are after share-based payments)
■
Improved operating margins in all three segments and across all geographic segments
■
Asia-Pacific moved into operating profit, with strongest revenue growth ion group at 62%.
■
Near-doubling of Central costs reflects inclusion of £2.5m previously attributed to Custom Research and £1.8m of additional costs relating to the LTIP; ex-these, increase was 37%.
■
Investment in technology: £4.4m (of which £3.9m was software); Investment in panel: £2.8m; other capex on PPE £1.0m
■
New offices Spain, Italy, India
■
Dividend increased by 50% to 3.0p
Exhibit 1: Summary results by segment
H118 (£m) |
Gth |
h218 (£m) |
Gth |
FY18 (£m) |
Gth / prior year |
Constant currency gth (%) |
|||||||||
Revenue |
|||||||||||||||
Data Products - Brand Index |
11.40 |
18% |
12.30 |
22% |
23.700 |
20% |
|||||||||
Data Products - Other |
2.98 |
129% |
3.76 |
25% |
6.746 |
56% |
|||||||||
Data Products - Total |
14.38 |
31% |
16.06 |
12% |
30.445 |
26% |
30% |
||||||||
Data Services - Omnibus |
12.70 |
24% |
14.52 |
25% |
27.219 |
24% |
|||||||||
Data Services - Other |
0.74 |
1% |
1.00 |
51% |
1.737 |
24% |
|||||||||
Data Services – Total |
13.44 |
22% |
15.52 |
26% |
28.956 |
24% |
26% |
||||||||
Custom Research |
29.135 |
-2% |
29.5 |
-3% |
58.657 |
-3% |
0% |
||||||||
Eliminations |
-0.64 |
134% |
-0.859 |
-1.499 |
50% |
||||||||||
GROUP TOTAL |
56.96 |
61.10 |
116.560 |
9% |
12% |
||||||||||
Operating Profit |
|||||||||||||||
Data Products - Total |
4.785 |
73% |
6.9 |
61% |
11.659 |
66% |
|||||||||
Data Services – Total |
3.511 |
41% |
4.5 |
39% |
8.002 |
40% |
|||||||||
Custom Research |
6.863 |
60% |
7.3 |
57% |
14.121 |
59% |
|||||||||
GROUP TOTAL |
15.16 |
59% |
18.62 |
54% |
33.782 |
56% |
|||||||||
Operating Margin |
|||||||||||||||
Data Products - Total |
33.3% |
42.8% |
38.3% |
29.2%^ |
|||||||||||
Data Services – Total |
26.1% |
28.9% |
27.6% |
24.6%^ |
|||||||||||
Custom Research |
23.6% |
24.6% |
24% |
14.8%^** |
|||||||||||
OPERATING MARGIN (pre-Central Costs) |
26.6% |
30.5% |
29.0% |
13.6%^** |
|||||||||||
Central Costs |
-6.329 |
-7.779 |
-14.108 |
98%** |
|||||||||||
Operating Profit |
8.830 |
10.84 |
19.674 |
35% |
|||||||||||
GROUP OPERATING MARGIN |
15.5% |
17.7% |
16.9% |
13.6%^ |
|||||||||||
Source: Company accounts Note: ^Prior year; ** change in allocation
The operating profit referred to here is as per the company’s definition, including share-based payments, and hence is a lower figure than that shown in our model excerpt in Exhibit 5, below.
Management believes that the current financial year has started well and it “remains confident of future growth potential”.
The statement contains detailed descriptions of the data products and services and the enhancements that are currently being assessed and launched. These all underline the group’s move further away from being a traditional project-led, consultancy-style business model of market research into a partner providing real-time data and analytics based on rich, connected data provided by the group’s in-house panel and sold on a subscription basis. The growth in the Data Products (BrandIndex, increasing coupled with Profiles, which accounts for the bulk of ‘other’ in the Data Products segment) and in Data Services (94% of which is Omnibus) clearly demonstrated this progress, which is reinforced by the change in the type of custom work being undertaken.
Exhibit 2: Adjustments to forecasts
EPS |
PBT |
EBITDA |
|||||||
Old |
New |
% chg. |
Old |
New |
% chg. |
Old |
New |
% chg. |
|
2018 |
14.3 |
15.6 |
+9 |
23.0 |
26.9 |
+17 |
22.3 |
24.6 |
+10 |
2019e |
15.8 |
17.2 |
+10 |
26.2 |
27.5 |
+5 |
25.5 |
26.5 |
+4 |
2020e |
- |
18.3 |
N/A |
- |
29.5 |
N/A |
- |
28.7 |
N/A |
Source: Company accounts, Edison
The FY18 figures were around 10% better than our previous forecasts, partly reflecting the small acquisitions that we had not built into the numbers, with a small additional benefit from currency, but mostly from good trading. The larger discrepancy in the adjusted PBT number shown in the table above is due to Edison’s policy on adding back the share-based payments to the adjusted figures. In this instance, the share-based payments were considerably higher than we had anticipated – double at £3.646m, reflecting the increased likelihood of a full payment – see below. Stripping these out, the difference between the FY18 adjusted PBT and our prior forecast is also 10%.
We have adjusted our FY19e forecasts, lifting our EBITDA number by 4% (to give 8% year-on-year growth), which may prove to be conservative if the trading momentum continues at the current rate. Forecast EPS is lifted by a greater amount, as we have altered our anticipated blended tax rate down from 25% to 23% to reflect the lower corporation tax now prevalent in the US.
New LTIP to overlap
The LTIP put in place in 2014 was based on five-year CAGR in earnings per share, with full payout requiring 25% growth in adjusted EPS. Other targets, such as an average operating margin of over 12% (which would happen even if the group was only to breakeven at the operating profit level in FY19e), and the trebling of share price needed to trigger a further payment to the CEO if the other targets are met in full, look very likely to have been achieved. 25% CAGR in EPS would be FY19e EPS of 17.9p on our basis, against our current forecast of 17.2p.
The new scheme that is being drawn up currently will overlap with the 2014 scheme for one year in order not to drive any short-termism that might be engendered by this target.
In mid-September, Oncology Venture (OV) provided an update on its focused Phase II study investigating LiPlaCis in heavily pre-treated metastatic breast cancer (mBC) patients. To date, 26 patients have been enrolled in the trial via the drug response predictor (DRP) screening programme. Nine patients were segmented into the top one-third of responders and of these, 55% achieved partial remission. Notably, only the top responders as identified by the DRP achieved this, which may suggest that the DRP could prospectively identify responders.